These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20626398)

  • 21. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
    Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential.
    Ghigo A; Hirsch E
    Recent Pat Inflamm Allergy Drug Discov; 2008 Jan; 2(1):1-10. PubMed ID: 19075988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death.
    Elis W; Triantafellow E; Wolters NM; Sian KR; Caponigro G; Borawski J; Gaither LA; Murphy LO; Finan PM; Mackeigan JP
    Mol Cancer Res; 2008 Apr; 6(4):614-23. PubMed ID: 18403640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting phosphoinositide 3-kinase gamma to fight inflammation and more.
    Barberis L; Hirsch E
    Thromb Haemost; 2008 Feb; 99(2):279-85. PubMed ID: 18278175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.
    Norman MH; Andrews KL; Bo YY; Booker SK; Caenepeel S; Cee VJ; D'Angelo ND; Freeman DJ; Herberich BJ; Hong FT; Jackson CL; Jiang J; Lanman BA; Liu L; McCarter JD; Mullady EL; Nishimura N; Pettus LH; Reed AB; Miguel TS; Smith AL; Stec MM; Tadesse S; Tasker A; Aidasani D; Zhu X; Subramanian R; Tamayo NA; Wang L; Whittington DA; Wu B; Wu T; Wurz RP; Yang K; Zalameda L; Zhang N; Hughes PE
    J Med Chem; 2012 Sep; 55(17):7796-816. PubMed ID: 22897589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isoform-Selective PI3K Inhibitors for Various Diseases.
    Bheemanaboina RRY
    Curr Top Med Chem; 2020; 20(12):1074-1092. PubMed ID: 31903879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3K inhibitors as novel cancer therapies: implications for cardiovascular medicine.
    McLean BA; Zhabyeyev P; Pituskin E; Paterson I; Haykowsky MJ; Oudit GY
    J Card Fail; 2013 Apr; 19(4):268-82. PubMed ID: 23582093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The biological effects of isoform-specific PI3-kinase inhibition.
    Ihle NT; Powis G
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):41-9. PubMed ID: 20047145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The chemical biology of phosphoinositide 3-kinases.
    Wymann MP; Schultz C
    Chembiochem; 2012 Sep; 13(14):2022-35. PubMed ID: 22965647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in subunits of PI3K class I in cancer.
    Cui W; Cai Y; Zhou X
    Pathology; 2014 Apr; 46(3):169-76. PubMed ID: 24614719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?
    Fougerat A; Gayral S; Malet N; Briand-Mesange F; Breton-Douillon M; Laffargue M
    Clin Sci (Lond); 2009 May; 116(11):791-804. PubMed ID: 19397491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterocyclic compounds and their uses: a patent evaluation of WO2010151735A2.
    Scozzafava A; Supuran CT
    Expert Opin Ther Pat; 2011 May; 21(5):803-6. PubMed ID: 21434841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular toxicity of PI3Kα inhibitors.
    Sadasivan C; Zhabyeyev P; Labib D; White JA; Paterson DI; Oudit GY
    Clin Sci (Lond); 2020 Oct; 134(19):2595-2622. PubMed ID: 33063821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K inhibitors as potential therapeutics for autoimmune disease.
    Ball J; Archer S; Ward S
    Drug Discov Today; 2014 Aug; 19(8):1195-9. PubMed ID: 24735732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome.
    Stalmans I
    Verh K Acad Geneeskd Belg; 2005; 67(4):229-76. PubMed ID: 16334858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [PI3K inhibitor].
    Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
    Park SJ; Min KH; Lee YC
    Respirology; 2008 Nov; 13(6):764-71. PubMed ID: 18811876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
    Thomas M; Owen C
    Curr Opin Pharmacol; 2008 Jun; 8(3):267-74. PubMed ID: 18394961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
    Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
    Rommel C; Camps M; Ji H
    Nat Rev Immunol; 2007 Mar; 7(3):191-201. PubMed ID: 17290298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.